Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Phase 2 part: Patients with confirmed diagnosis of MF who meet all of the following criteria:~* ANC ≥ 1 x 10\^9/L without the assistance of granulocyte growth factors~* Peripheral blood blast count \<10%~* ECOG performance status ≤ 2.~* Adequate hematological, renal, hepatic, and coagulation laboratory assessments~* No prior treatment with a BET inhibitor~* Patients must give written informed consent to participate in this study before the performance of any study-related procedure.~For Arm 1 and 2 the following criteria should be considered:~* Patients with confirmed diagnosis of MF who meet all of the following criteria~* Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher~* Spleen volume ≥ 450 cm\^3 by MRI or CT for Cohorts 1B and 2B OR RBC transfusion dependent (defined as an average of ≥2 units of RBC transfusions per month (total of greater than 6 RBC transfusions) over the 12 weeks prior to enrollment for Cohorts 1A and 2A)~* At least 2 symptoms measurable (Score ≥ 1) using the Myelofibrosis Symptom Assessment Form Version 4.0 (MFSAF v4.0)~* Platelet count ≥ 75 x 10\^9/L without the assistance of thrombopoietic factors or transfusions for at least 14 days~* Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant, resistant, refractory, or lost response to the JAK inhibitor; have not received the JAK inhibitor within 2 weeks prior to the start of study drug, or are ineligible to be treated with a JAK inhibitor~* Combination Arm (Arm 2): Must have received single agent ruxolitinib and be on a stable dose for a minimum 8 weeks but have disease that is not being adequately controlled by ruxolitinib~For Arm 3 (JAK inhibitors naïve) the following criteria should be considered:~* Patients with confirmed diagnosis of MF who meet all of the following criteria~* Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher~* Platelet count ≥ 100 x 10\^9/L without the assistance of thrombopoietic factors or transfusions~* Spleen volume ≥ 450 cm\^3 by MRI/CT~* At least 2 symptoms measurable (Score ≥ 3) or a total score of ≥ 10 using the Myelofibrosis Symptom Assessment Form Version 4.0 ( MFSAF v4.0)~* No prior treatment with JAKi allowed~For Arm 4 (ET Expansion) the following criteria should be considered:~* Patients with a confirmed diagnosis of ET~* High-risk disease, defined as meeting at least one of the following criteria:~* Age \> 60 years~* Platelet count \> 1500 × 10\^9/L (at any point during the patient's disease)~* Previously documented thrombosis, erythromelalgia, or migraine~* Previous hemorrhage related to ET~* Diabetes or hypertension requiring pharmacological therapy for \> 6 months~* Have ≥2 symptoms with an average score ≥ 3 over the 7-day period prior to Cycle 1 Day 1 or an average total score of ≥15 over the 7-day period prior to Cycle 1 Day 1 using the using the MPN SAF~  * Platelets \> 600 × 10\^9/L~ * Resistant or intolerant to HU~Exclusion Criteria:~* Current known active or chronic infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C.~* Impaired cardiac function or clinically significant cardiac diseases~* Patients with Child-Pugh Class B or C~* Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of pelabresib and/or ruxolitinib, including any unresolved nausea, vomiting, or diarrhea that is CTCAE Grade \>1~* Prior treatment with a BET inhibitor.~* Pregnant or lactating women~* Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study~* Patients unwilling or unable to comply with this study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm (MF patients treated with pelabresib alone) (Type: EXPERIMENTAL): * Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi (pelabresib alone)~* Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)
- Arm 2: Prior JAKi Combination Arm (Type: EXPERIMENTAL): * Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib (pelabresib + Ruxolitinib)~* Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)
- Arm 3: JAKi Naïve Combination Arm (Type: EXPERIMENTAL): Open to patients with MF who have not previously received a JAKi (pelabresib + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
- Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm (Type: EXPERIMENTAL): Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete